Vildagliptin and Metformin Hydrochloride

Description

ELLGLIPT-M 500 is a potent, dual-action oral antidiabetic formulation by Ellanjey Lifesciences that combines Vildagliptin (50 mg) – a highly selective DPP-4 inhibitor – with Metformin Hydrochloride (500 mg) – the established first-line biguanide. This fixed-dose combination is indicated for the treatment of type 2 diabetes mellitus in patients whose blood glucose levels are not adequately controlled on metformin alone or who are already on the combination of vildagliptin and metformin as separate tablets.

Key Benefits:

• Dual Mechanism of Action – Vildagliptin (incretin-based) + Metformin (insulin sensitizer) for comprehensive glucose control.

• Enhances Incretin Hormones – Vildagliptin increases GLP-1 and GIP, stimulating insulin release when glucose is high.

• Reduces Glucose Production – Metformin lowers hepatic glucose output and improves insulin sensitivity.

• Weight Neutral – Unlike sulfonylureas, vildagliptin does not cause weight gain; metformin is weight neutral.

• Low Risk of Hypoglycemia – Vildagliptin is glucose-dependent (only works when blood sugar is elevated).

• Beta-Cell Preservation – DPP-4 inhibitors may preserve pancreatic beta-cell function over time.

FAQs:

1. How does Vildagliptin differ from Metformin in controlling diabetes?
Vildagliptin increases insulin secretion when glucose is high (glucose-dependent), while metformin reduces liver glucose production and improves insulin sensitivity – they work best together.

2. Does Ellglipt-M 500 cause weight gain?
No – vildagliptin is weight neutral and metformin is weight neutral or promotes modest weight loss. This is a major advantage over sulfonylureas and insulin.

3. Can Ellglipt-M 500 cause low blood sugar (hypoglycemia)?
Very low risk when taken as directed. Vildagliptin only increases insulin when blood sugar is elevated. Hypoglycemia risk increases if you skip meals, exercise excessively, or take with sulfonylureas/insulin.

4. Is Ellglipt-M 500 safe for patients with kidney disease?
Metformin is contraindicated in severe kidney disease (eGFR <30). For mild to moderate kidney disease, your doctor may adjust the dose or consider alternatives. Always inform your doctor about your kidney function.